Drug intelligence / Profile preview

dual-AAV.Var4 STRC

Development stage: Preclinical
Lead developer: Medizinische Hochschule Hannover
Modality: Gene Therapies
Administration: Otic

Overview

**dual-AAV.Var4 STRC** is a preclinical inner-ear gene-replacement therapy designed for autosomal recessive nonsyndromic hearing loss caused by pathogenic variants in the **stereocilin gene**. It uses the outer-hair-cell-tropic AAV capsid variant Var4 in a dual-AAV RNA-trans-splicing system, with each vector carrying a portion of the large STRC coding sequence. Co-delivery is intended to reconstitute full-length stereocilin expression in cochlear outer hair cells, restore stereociliary architecture, and improve auditory function. In mature Strc-deficient mice, the system produced persistent STRC expression, partial outer-hair-cell stereocilia rescue, and partial improvement in auditory brainstem response thresholds.

Other names: dual-AAV.Var4

Beyond the preview

Go deeper on dual-AAV.Var4 STRC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dual-AAV.Var4 STRC.

Explore the full profile